News

- 14 DEC 2020
PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for its Clinical Trial Product
LAGUNA HILLS, CA, December 14, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has commenced additional physical parameter testing of its CypCaps® product for pancreatic cancer, in line with the recommendations
Read more →
- Posted in
- News
- 02 DEC 2020
PharmaCyte Biotech Successfully Completes 9-Month Stability Study
LAGUNA HILLS, CA, December 2, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the nine-months product stability testing that is required by the U.S. Food and Drug Administration
Read more →
- Posted in
- News
- 04 NOV 2020
PharmaCyte Biotech Receives U.S. FDA Clinical Hold Letter
LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received the clinical hold letter from the U.S. Food and Drug Administration (FDA) with respect to its Investigational New Drug Application (IND).
Read more →
- Posted in
- News
- 02 OCT 2020
PharmaCyte Biotech’s Investigational New Drug Application Placed on Hold by the U. S. FDA
LAGUNA HILLS, CA, October 2, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that the company’s submitted Investigational New Drug
Read more →
- Posted in
- News
- 23 SEP 2020
PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period
LAGUNA HILLS, CA, September 23, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it continues to engage with the U.S. Food and Drug Administration (FDA) during its 30-day comment period regarding
Read more →
- Posted in
- News
- 14 SEP 2020
PharmaCyte Biotech Successfully Completes Six-Month Stability Study
LAGUNA HILLS, CA, September 14, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the six-month product stability testing that is required by the U.S. Food and Drug
Read more →
- Posted in
- News
- 08 SEP 2020
PharmaCyte Biotech Successfully Completes Second Container Closure Integrity Test
LAGUNA HILLS, CA, September 8, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the second Container Closure Integrity (CCI) test that is required by the U.S. Food
Read more →
- Posted in
- News
- 02 SEP 2020
PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic Cancer
LAGUNA HILLS, CA, September 2, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for
Read more →
- Posted in
- News
- 10 AUG 2020
PharmaCyte Biotech Appoints Dr. José Iglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic Cancer
LAGUNA HILLS, CA, August 10, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has appointed José L. Iglesias M.D. as Consulting Chief
Read more →
- Posted in
- News
- 05 AUG 2020
FDA Formally Accepts PharmaCyte Biotech’s Drug Master File for Company’s Pancreatic Cancer Therapy
LAGUNA HILLS, CA, August 5, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the Drug Master File (DMF) that its partner, Austrianova, filed with the U.S. Food and Drug Administration (FDA) has
Read more →
- Posted in
- News

PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for its Clinical Trial Product

PharmaCyte Biotech Successfully Completes 9-Month Stability Study

PharmaCyte Biotech Receives U.S. FDA Clinical Hold Letter

PharmaCyte Biotech’s Investigational New Drug Application Placed on Hold by the U. S. FDA

PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period

PharmaCyte Biotech Successfully Completes Six-Month Stability Study

PharmaCyte Biotech Successfully Completes Second Container Closure Integrity Test

PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic Cancer

PharmaCyte Biotech Appoints Dr. José Iglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic Cancer

FDA Formally Accepts PharmaCyte Biotech’s Drug Master File for Company’s Pancreatic Cancer Therapy

Contact Us

Latest News

Subscribe to Our Mailing List